News & media

Here you can find our news and media resources. To comply with applicable regulation in Denmark, press releases and company announcements concerning specific medicinal products or investigational candidates in late-stage development are removed from our website within three weeks of publication. Please contact us to request a copy.

  • PRESS RELEASE

    Zealand Pharma to participate in the Jefferies London Healthcare Conference

  • COMPANY ANNOUNCEMENT

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

  • COMPANY ANNOUNCEMENT

    Zealand Pharma Announces Financial Results for the First Nine Months of 2024

  • PRESS RELEASE

    Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results

  • COMPANY ANNOUNCEMENT

    Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism

  • COMPANY ANNOUNCEMENT

    Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide

  • COMPANY ANNOUNCEMENT

    Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024

  • PRESS RELEASE

    Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th

  • COMPANY ANNOUNCEMENT

    Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

  • COMPANY ANNOUNCEMENT

    Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

  • COMPANY ANNOUNCEMENT

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

  • COMPANY ANNOUNCEMENT

    Total number of shares and voting rights in Zealand Pharma on August 30, 2024

Corporate management

  • Adam ALR0640

    Adam Steensberg - President and Chief Executive Officer

  • Zealand Pharma 0285 FIN

    Adam Steensberg - President and Chief Executive Officer

  • Christina ALR0693 V2

    Christina Sonnenborg Bredal - Executive Vice President and Chief People Officer

  • David ALR1003

    David Kendall - Executive Vice President, Research & Development and Chief Medical Officer

  • Henriette ALR0758

    Henriette Wennicke - Executive Vice President and Chief Financial Officer

  • Ivan ALR0873

    Ivan Møller - Executive Vice President and Chief Operating Officer

Research and development

Logos and icons

Zealand Pharma 1503

Stay up-to-date with the latest news from Zealand

Sign-up to receive press releases and company announcements directly to your inbox

Subscribe to news

Investor and Media contacts

  • Anna Krassowksa (1)

    Anna Krassowska

    Vice President, Investor Relations & Corporate Communications

    Email Anna